Advertisement
Research Article| Volume 32, ISSUE 6, P451-459, June 2022

Longer-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3

Published:April 12, 2022DOI:https://doi.org/10.1016/j.nmd.2022.04.003

      Highlights

      • 37 adults with SMA 2–3 treated with nusinersen, followed for up to 30 months of treatment.
      • Median MRC score increased from baseline to visits at 6 and 14 months, not afterwards.
      • The median rate of MRC score increase was 1.85 points per year.
      • Revised hammersmith scale median score increased only from baseline to 6 months.
      • Revised hammersmith scale's calculated annual rate of change was 0 points.

      Abstract

      The effectiveness of nusinersen treatment in patients with spinal muscular atrophy (SMA) was established in clinical trials only for pediatric patients. Few cohort studies confirmed its benefit in adults up to 22 months of treatment. We report a longer-term observation of nusinersen treatment effects and safety in a large cohort of adult patients. Patients with SMA type 2 and 3 treated with nusinersen at Tel-Aviv Medical Center between March 2018 and September 2020 were prospectively recruited. Neurological impairment, motor, respiratory function, and side effects were recorded. We compared baseline measurements with those after 6, 14, and 26 months of treatment and calculated the annual rates of change. Overall, 37 patients were treated (21–64 years old). 16 completed 26 months, and 8 completed 30 months of treatment. The median score on the Medical Research Council strength scale increased from baseline to visits at 6 and 14 months (p ≤ 0.03), but not afterwards, with a median increase of 1.85 points per year. Revised Hammersmith Scale median score increased only from baseline to 6 months (p = 0.02), with a calculated annual rate of change of 0 points. No significant change was noticed in the respiratory function. The only side effect was post lumbar puncture headache. In conclusion, our study further supports the efficacy and safety of nusinersen treatment in adult patients with SMA2 and SMA3, with modest improvement in muscle strength, and stabilization of motor function over a relatively long period of observation.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Neuromuscular Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lunn M.R.
        • Wang C.H.
        Spinal muscular atrophy.
        The Lancet, 2008 (Vol. 371)
        • Mercuri E.
        • Finkel R.S.
        • Muntoni F.
        • Wirth B.
        • Montes J.
        • Main M.
        • et al.
        Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.
        Neuromuscul Disord. 2018; 28
        • Wadman R.I.
        • Wijngaarde C.A.
        • Stam M.
        • Bartels B.
        • Otto L.A.M.
        • Lemmink H.H.
        • et al.
        Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c–4.
        Eur J Neurol. 2018; 25
        • Deymeer F.
        • Serdaroglu P.
        • Parman Y.
        • Poda M.
        Natural history of SMA IIIb: muscle strength decreases in a predictable sequence and magnitude.
        Neurology. 2008; 71
        • Mazzone E.
        • De Sanctis R.
        • Fanelli L.
        • Bianco F.
        • Main M.
        • Van den Hauwe M.
        • et al.
        Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients.
        Neuromuscul Disord. 2014; 24
        • Mercuri E.
        • Finkel R.
        • Montes J.
        • Mazzone E.S.
        • Sormani M.P.
        • Main M.
        • et al.
        Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials.
        Neuromuscul Disord. 2016; 26
        • Piepers S.
        • Van Den Berg L.H.
        • Brugman F.
        • Scheffer H.
        • Ruiterkamp-Versteeg M.
        • Van Engelen B.G.
        • et al.
        A natural history study of late onset spinal muscular atrophy types 3b and 4.
        J Neurol. 2008; 255
        • Groen E.J.N.
        • Talbot K.
        • Gillingwater T.H.
        Advances in therapy for spinal muscular atrophy: promises and challenges.
        Nature Rev Neurol. 2018;
        • Finkel R.S.
        • Mercuri E.
        • Darras B.T.
        • Connolly A.M.
        • Kuntz N.L.
        • Kirschner J.
        • et al.
        Nusinersen versus sham control in infantile-onset spinal muscular atrophy.
        N Engl J Med. 2017; 377
        • Mercuri E.
        • Darras B.T.
        • Chiriboga C.A.
        • Day J.W.
        • Campbell C.
        • Connolly A.M.
        • et al.
        Nusinersen versus sham control in later-onset spinal muscular atrophy.
        N Engl J Med. 2018; 378
        • Michelson D.
        • Ciafaloni E.
        • Ashwal S.
        • Lewis E.
        • Narayanaswami P.
        • Oskoui M.
        • et al.
        Evidence in focus: nusinersen use in spinal muscular atrophy report of the guideline development, dissemination, and implementation subcommittee of the american academy of neurology.
        Neurology. 2018; 91
        • Al-Zaidy S.A.
        • Kolb S.J.
        • Lowes L.
        • Alfano L.N.
        • Shell R.
        • Church K.R.
        • et al.
        AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort.
        J Neuromuscul Dis. 2019; 6
        • De Wel B.
        • Goosens V.
        • Sobota A.
        • Van Camp E.
        • Geukens E.
        • Van Kerschaver G.
        • et al.
        Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
        J Neurol [Internet]. 2020; 268 (Available from:): 923-935https://doi.org/10.1007/s00415-020-10223-9
        • Maggi L.
        • Bello L.
        • Bonanno S.
        • Govoni A.
        • Caponnetto C.
        • Passamano L.
        • et al.
        Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3.
        J Neurol Neurosurg Psychiatry. 2020; 91: 1166-1174
        • Hagenacker T.
        • Wurster C.D.
        • Günther R.
        • Schreiber-Katz O.
        • Osmanovic A.
        • Petri S.
        • et al.
        Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study.
        Lancet Neurol [Internet]. 2020; 19 (Available from:): 317-325https://doi.org/10.1016/S1474-4422(20)30037-5
        • Veerapandiyan A.
        • Eichinger K.
        • Guntrum D.
        • Kwon J.
        • Baker L.
        • Collins E.
        • et al.
        Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience.
        Muscle Nerve. 2020; 61
        • Pechmann A.
        • König K.
        • Bernert G.
        • Schachtrup K.
        • Schara U.
        • Schorling D.
        • et al.
        SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy.
        Orphanet J Rare Dis. 2019; 14
        • Wang C.H.
        • Finkel R.S.
        • Bertini E.S.
        • Schroth M.
        • Simonds A.
        • Wong B.
        • et al.
        Consensus statement for standard of care in spinal muscular atrophy.
        J Child Neurol. 2007; 22
      1. Finkel R.S., Sejersen T., Mercuri E., Bertini E., Chen K., Crawford T.O., et al. 218th ENMC International Workshop:: Revisiting the consensus on standards of care in SMA Naarden, The Netherlands, 19–21 February 2016. In: neuromuscular Disorders. 2017.

        • Wijngaarde C.A.
        • Stam M.
        • Otto L.A.M.
        • Bartels B.
        • Asselman F.L.
        • van Eijk R.P.A.
        • et al.
        Muscle strength and motor function in adolescents and adults with spinal muscular atrophy.
        Neurology. 2020; 95: e1988-e1998
        • Ramsey D.
        • Scoto M.
        • Mayhew A.
        • Main M.
        • Wilson I.
        • Mazzone E.
        • et al.
        Revised Hammersmith scale for spinal muscular atrophy.
        Neuromuscul Disord. 2015; 25
        • Ramsey D.
        • Scoto M.
        • Mayhew A.
        • Main M.
        • Mazzone E.S.
        • Montes J.
        • et al.
        Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool.
        PLoS ONE. 2017; 12
        • Cedarbaum J.M.
        • Stambler N.
        • Malta E.
        • Fuller C.
        • Hilt D.
        • Thurmond B.
        • et al.
        The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).
        J Neurol Sci. 1999; 169
        • Konersman C.G.
        • Ewing E.
        • Yaszay B.
        • Naheedy J.
        • Murphy S.
        • Skalsky A
        Nusinersen treatment of older children and adults with spinal muscular atrophy.
        Neuromuscul Disord [Internet]. 2020; (xxxx). Available from:https://doi.org/10.1016/j.nmd.2020.12.006
        • Mercuri E.
        • Lucibello S.
        • Pera M.C.
        • Carnicella S.
        • Coratti G.
        • De Sanctis R.
        • et al.
        Long-term progression in type II spinal muscular atrophy: a retrospective observational study.
        Neurology. 2019; 93
        • Stolte B.
        • Bois J.M.
        • Bolz S.
        • Kizina K.
        • Totzeck A.
        • Schlag M.
        • et al.
        Minimal clinically important differences in functional motor scores in adults with spinal muscular atrophy.
        Eur J Neurol. 2020; 27: 2586-2594
        • McGraw S.
        • Qian Y.
        • Henne J.
        • Jarecki J.
        • Hobby K.
        • Yeh W.S.
        A qualitative study of perceptions of meaningful change in spinal muscular atrophy.
        BMC Neurol. 2017; 17
        • Sivo S.
        • Mazzone E.
        • Antonaci L.
        • De Sanctis R.
        • Fanelli L.
        • Palermo C.
        • et al.
        Upper limb module in non-ambulant patients with spinal muscular atrophy: 12 month changes.
        Neuromuscul Disord. 2015; 25
        • Frazier K.S.
        Antisense Oligonucleotide Therapies:the Promise and the Challenges from a Toxicologic Pathologist's Perspective.
        Toxicol Pathol. 2015; 43: 78-89
      2. FDA. Nusinersen BLA. 2015; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207958Orig1s000ChemR.pdf